Gelonghui February 20 丨Huadong Pharmaceutical (000963.SZ) stated on February 15, 2023 at 14:30-16:00; on February 16, 11:00-11:40 and 14:00-15:00 during on-site research by the agency, that the company's Belling series and acarbose series products are expected to grow steadily this year, an improvement over the previous two years. The company's important varieties of diabetes pipelines are also expected to continue to grow at a relatively rapid pace this year. Both indications of liraglutide injections are expected to be approved for marketing this year, bringing new increases. Immunosuppressant products have maintained steady growth, and core products in the cardiovascular field have maintained rapid growth. Carbifene acetate for injection, micafennet sodium for injection, as well as newly approved sorafenib tablets and cagalacin tablets, etc. are also expected to have a positive impact on the company's business performance this year. In addition, the company is responsible for marketing Nihina® (Alogliptin benzoate tablets), epicaritin softgels, etc. are also expected to contribute to some sales performance. The company collaborated with Keji Pharmaceutical to commercialize the zevocene injection in China submitted a marketing license application in October 2022 and is currently in the review stage.
华东医药(000963.SZ):糖尿病管线的重要品种今年有望继续保持较快增长
Huadong Pharmaceutical (000963.SZ): Important varieties of diabetes pipelines are expected to continue to grow rapidly this year
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.